Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Sarcoma 3Neoplasms 3Brain Neoplasms 3Thyroid Carcinoma, Anaplastic 2Sarcoma, Synovial 2Prostatic Neoplasms 2Neurofibrosarcoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Gliosarcoma 2Glioblastoma 2Dermatofibrosarcoma 2Carcinoma, Renal Cell 2Breast Neoplasms 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1Somatostatinoma 1Solid Neoplasm 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Recurrent Uterine Corpus Sarcoma 1Recurrent Lymphoepithelioma of the Nasopharynx 1Pheochromocytoma 1Perivascular Epithelioid Cell Neoplasms 1Paraganglioma, Extra-Adrenal 1Paraganglioma 1Ovarian Neoplasms 1

Interventions

veliparib 1tipifarnib 1pazopanib 1Mitozytrex 1Mitomycin 1Immunoglobulin G 1Erlotinib Hydrochloride 1Disulfides 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Solid Neoplasm × pazopanib × Clear all
NCT01552356 2026-04-13

Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
54 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡